Core Viewpoint - The BroncTarget® lung denervation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its innovative technology and clinical value [1] Group 1: Product Overview - The BroncTarget® system is a targeted lung denervation technology aimed at treating moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] - It utilizes a bronchoscopic approach to deliver radiofrequency energy precisely to nerve targets, aiming to suppress airway hypercontraction and mucus hypersecretion [1] - The system offers a new treatment option for patients whose symptoms remain poorly controlled despite conventional drug therapy, integrating an "intervention + medication" management strategy [1] Group 2: Technological Features - The BroncTarget® system features innovative designs such as circular multi-electrodes, adjustable orifices, differentiated radiofrequency energy output, real-time temperature and impedance monitoring, and intelligent saline infusion [1] - These features ensure the efficiency and safety of radiofrequency ablation [1] Group 3: Clinical Trials - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted simultaneously across 28 hospitals nationwide [2]